The system is marketed to companies developing biopharmaceuticals including novel compounds and biosimilars with an emphasis on therapeutic monoclonal antibodies.
BioFactura president and CEO Darryl Sampey said the company intends to make StableFast platform available to many clients in the private and government sectors who look forward for the development of lifesaving drugs.
StableFast was commercially launched in the earlier part of this year.